Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

Lancet Oncol. 2005 Jun;6(6):383-91. doi: 10.1016/S1470-2045(05)70176-5.


Background: Some oestrogen-receptor (ER) positive breast cancers express epidermal growth factor receptor (EGFR), but whether inhibition of EGFR can suppress proliferation of breast cancer cells and ER function is not known.

Methods: In a double-blind, placebo-controlled randomised trial of 56 postmenopausal patients with ER-positive and EGFR-positive primary breast cancer, 27 women were randomly assigned to the tyrosine-kinase inhibitor of EGFR gefitinib (250 mg given orally once a day) and the aromatase inhibitor anastrozole (1 mg given orally once a day), and 29 women to gefitinib (250 mg given orally once a day) and placebo of identical appearance to anastrozole given orally once a day, all given for 4-6 weeks before surgery. Primary outcome was inhibition of tumour-cell proliferation, as measured by Ki67 antigen labelling index. Secondary outcomes were reduction in EGFR phosphorylation at Tyr 845, reduction in ER phosphorylation at Ser 118, tumour size, and toxic effects. Analyses were by intention to treat.

Findings: Patients assigned gefitinib and anastrozole had a greater reduction from pretreatment values in proliferation-related Ki67 labelling index than did those assigned gefitinib alone (mean % reduction 98.0 [95% CI 96.1-98.9] vs 92.4 [85.1-96.1]; difference between groups 5.6% [5.1-6.0], p=0.0054). Tumour size was reduced by 30-99% (partial response) in 14 of 28 patients assigned gefitinib and [corrected]in 12 of 22 assigned gefitinib, as assessed by ultrasonography. Reduction in phosphorylation of ER at Ser 118 was similar for both groups. Treatment was well tolerated and much the same for both groups.

Interpretation: Single-agent gefitinib and gefitinib combined with anastrozole are well-tolerated and effective treatments for reducing the size of breast tumours and levels of ER phosphorylation when given as neoadjuvant therapy.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anastrozole
  • Antineoplastic Agents, Hormonal / administration & dosage*
  • Aromatase Inhibitors / administration & dosage
  • Breast Neoplasms / diagnostic imaging
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Double-Blind Method
  • England
  • ErbB Receptors / antagonists & inhibitors
  • Female
  • Gefitinib
  • Humans
  • Ki-67 Antigen
  • Middle Aged
  • Neoadjuvant Therapy
  • Neoplasms, Hormone-Dependent / diagnostic imaging
  • Neoplasms, Hormone-Dependent / drug therapy*
  • Neoplasms, Hormone-Dependent / pathology
  • Nitriles / administration & dosage*
  • Postmenopause
  • Protein Kinase Inhibitors / administration & dosage
  • Quinazolines / administration & dosage*
  • Receptors, Estrogen / antagonists & inhibitors
  • Treatment Outcome
  • Triazoles / administration & dosage*
  • Ultrasonography


  • Antineoplastic Agents, Hormonal
  • Aromatase Inhibitors
  • Ki-67 Antigen
  • Nitriles
  • Protein Kinase Inhibitors
  • Quinazolines
  • Receptors, Estrogen
  • Triazoles
  • Anastrozole
  • ErbB Receptors
  • Gefitinib